Back to Eli Lilly

Eli Lilly News

LLY

LLY: Eli Lilly Completes $8.94B Debt Offering

Eli Lilly (LLY) raised $8.94B via multi-series notes maturing 2028–2066 on 2026-05-20. Analysis of balance-sheet impact, leverage and investor considerations.

20 May 2026ELI LILLY & Co
LLY

LLY: Eli Lilly Advances Biotech Acquisitions

Eli Lilly (LLY) reports multiple biotech acquisitions and related charges; impact on financials, strategy, and investor risks as of 2025-10-30.

30 October 2025ELI LILLY & Co
LLY

LLY: Eli Lilly Divests Cialis Rights Abroad

Eli Lilly (LLY) sells Cialis rights in select non-U.S. markets for $180M on 2025-10-30. Investor implications and context for LLY shareholders.

30 October 2025ELI LILLY & Co
LLY

LLY: Eli Lilly Reports Key FDA Approvals

Oct 30, 2025 — Eli Lilly (LLY) reports FDA approvals and positive Phase 3 results, including SURMOUNT‑1's 94% T2D risk reduction in pre‑diabetics.

30 October 2025ELI LILLY & Co
LLY

LLY Dividend Q3 2025: Raised 15% to $1.50

Eli Lilly (LLY) raises Q3 2025 dividend 15% to $1.50 per share. Coverage of payout implications, buybacks, balance sheet and risks tied to product concentration.

30 October 2025ELI LILLY & Co
LLY

LLY Q3 2025: Revenue Up 54% — Guidance Raised

Eli Lilly (LLY) Q3 2025 revenue rose 54% and the company raised full-year guidance. Net income, buybacks, debt and product drivers explained.

30 October 2025ELI LILLY & Co
All news